Trial Profile
A study to evaluate the virologic response after switching from antiretroviral therapy to a dolutegravir-based regimen in HIV patients: week 48 results in an observational cohort
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2018
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- 08 Mar 2018 Results assessing virologic response of switching from ongoing cART to a dolutegravir-based regimen at week 48 (n=239), published in the Journal of Antimicrobial Chemotherapy
- 26 Jul 2017 Week 48 results in a prospective cohort presented at the 9th International AIDS Society Conference on HIV Science
- 29 Dec 2016 New trial record